Sun Sep 15 13:40:10 UTC 2024: Please provide me with the text you would like me to summarize and rewrite as a news article. I need the text content to be able to complete your request.
Ten-Year Data for Merck’s KEYTRUDA ® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Ten-Year Data for Merck's KEYTRUDA ® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
First Piper 